References
- HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2011National Cancer InstituteBethesda, MD Available from: http://seer.cancer.gov/csr/1975_2011/ based on 2013 SEER data submissionAccessed June 10, 2016
- SchorgeJOModesittSCColemanRLSGO White Paper on ovarian cancer: etiology, screening and surveillanceGynecol Oncol20101191 7 1720692025
- JordanMAWilsonLMicrotubules as a target for anticancer drugsNat Rev Cancer200444 253 26515057285
- SchwartzELAntivascular actions of microtubule-binding drugsClin Cancer Res2009158 2594 260119351751
- McGuireWPRowinskyEKRosenheinNBTaxol: a unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasmsAnn Intern Med19891114 273 2792569287
- SledgeGWJrRobertNSparanoJAPaclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experienceSemin Oncol1994215 Suppl 8 15 18
- BonomiPKimKBKuglerJComparison of survival for stage IIIB versus stage IV non-small cell lung cancer (NSCLC) patients with etoposide-cisplatin versus taxol-cisplatin: an Eastern Cooperative Oncology Group (ECOG) trialProc Am Soc Clin Oncol199716 454a
- VaseyPAJaysonGCGordonAScottish Gynaecological Cancer Trials GroupPhase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinomaJ Nat Cancer Inst20049622 1682 169115547181
- DavidsonBTropéCGOvarian cancer: diagnostic, biological and prognostic aspectsWomens Health (Lond)2014105 519 53325335543
- GottesmanMMFojoTBatesSEMultidrug resistance in cancer: role of ATP-dependent transportersNat Rev Cancer200221 48 5811902585
- ThomasHColeyHMOvercoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoproteinCancer Contl2003102 159 165
- MickischGHMerlinoGTGalskiHGottesmanMMPastanITransgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistanceProc Natl Acad Sci U S A1991882 547 5511671173
- AmbudkarSVDeySHrycynaCARamachandraMPastanIGottesmanMMBiochemical, cellular, and pharmacological aspects of the multidrug transporterAnn Rev Pharmacol Toxicol199939 361 39810331089
- PalmeiraASousaEVasconcelosMHPintoMMThree decades of P-gp inhibitors: skimming through several generations and scaffoldsCurr Med Chem20121913 1946 202522257057
- JangSHWientjesMGAuJLKinetics of P-glycoprotein-mediated efflux of paclitaxelJ Pharmacol Exp Ther20012983 1236 124211504826
- DohleDSPasaSDGustmannSChick ex ovo culture and ex ovo CAM assay; how it really worksJ Vis Exp200933 e1620
- LindhagenENygrenPLarssonRThe fluorometric microculture cytotoxicity assayNat Protoc200838 1364 136918714304
- TigheAJohnsonVLAlbertellaMTaylorSSAneuploid colon cancer cells have a robust spindle checkpointEMBO Rep200127 609 61411454737
- WaldmanTKinzlerKWVogelsteinBp21 is necessary for the p53-mediated G1 arrest in human cancer cellsCancer Res19955522 5187 51907585571
- LooDTRillemaJRMeasurement of cell deathMethods Cell Biol199857 251 2649648109
- GalbraithSMChaplinDJLeeFEffects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivoAnticancer Res2001211A 93 10211299795
- BurnsCJFantinoEPhillipsIDCYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivoMol Cancer Ther2009811 3036 304519887548
- PasquierESinnappanSMunozMAKavallarisMENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting propertiesMol Cancer Ther201095 1408 141820442304